Follow
Manuel Romero-Gómez
Manuel Romero-Gómez
Catedrático de Medicina, Universidad de Sevilla.
Verified email at us.es - Homepage
Title
Cited by
Cited by
Year
A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement
M Eslam, PN Newsome, SK Sarin, QM Anstee, G Targher, ...
Journal of hepatology 73 (1), 202-209, 2020
29022020
Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection
N Afdhal, S Zeuzem, P Kwo, M Chojkier, N Gitlin, M Puoti, ...
New England Journal of Medicine 370 (20), 1889-1898, 2014
21462014
Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis
E Vilar-Gomez, Y Martinez-Perez, L Calzadilla-Bertot, A Torres-Gonzalez, ...
Gastroenterology 149 (2), 367-378. e5, 2015
20812015
Genomewide Association Study of Severe Covid-19 with Respiratory Failure
D Ellinghaus, F Degenhardt, L Bujanda, M Buti, A Albillos, P Invernizzi, ...
New England Journal of Medicine, 2020
1834*2020
Modeling nafld disease burden in china, france, germany, italy, japan, spain, united kingdom, and united states for the period 2016–2030
C Estes, QM Anstee, MT Arias-Loste, H Bantel, S Bellentani, J Caballeria, ...
Journal of hepatology 69 (4), 896-904, 2018
14872018
Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period.(vol 129, pg 512, 2005)
RJ Andrade, MI Lucena, MC Fernandez, G Pelaez, K Pachkoria, ...
Gastroenterology 129 (5), 1808-1808, 2005
1342*2005
Treatment of NAFLD with diet, physical activity and exercise
M Romero-Gómez, S Zelber-Sagi, M Trenell
Journal of hepatology 67 (4), 829-846, 2017
11532017
Elafibranor, an agonist of the peroxisome proliferator− activated receptor− α and− δ, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening
V Ratziu, SA Harrison, S Francque, P Bedossa, P Lehert, L Serfaty, ...
Gastroenterology 150 (5), 1147-1159. e5, 2016
10992016
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
ZM Younossi, V Ratziu, R Loomba, M Rinella, QM Anstee, Z Goodman, ...
The Lancet 394 (10215), 2184-2196, 2019
10292019
Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients
M Romero-Gómez, MDM Viloria, RJ Andrade, J Salmerón, M Diago, ...
Gastroenterology 128 (3), 636-641, 2005
9222005
Nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates
Z Younossi, M Stepanova, JP Ong, IM Jacobson, E Bugianesi, A Duseja, ...
Clinical Gastroenterology and Hepatology 17 (4), 748-755. e3, 2019
6502019
Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis
S McPherson, T Hardy, JF Dufour, S Petta, M Romero-Gomez, M Allison, ...
The American journal of gastroenterology 112 (5), 740, 2017
6502017
Fibrosis severity as a determinant of cause-specific mortality in patients with advanced nonalcoholic fatty liver disease: a multi-national cohort study
E Vilar-Gomez, L Calzadilla-Bertot, VWS Wong, M Castellanos, ...
Gastroenterology 155 (2), 443-457. e17, 2018
6432018
Subclinical hepatic encephalopathy predicts the development of overt hepatic encephalopathy
M Romero-Gómez, F Boza, MS Garcı́a-Valdecasas, E Garcı́a, ...
The American journal of gastroenterology 96 (9), 2718-2723, 2001
5592001
Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles
MI Lucena, M Molokhia, Y Shen, TJ Urban, GP Aithal, RJ Andrade, ...
Gastroenterology 141 (1), 338-347, 2011
4962011
Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment
JM Sánchez–Tapias, M Diago, P Escartín, J Enríquez, M Romero–Gómez, ...
Gastroenterology 131 (2), 451-460, 2006
4712006
Value of the critical flicker frequency in patients with minimal hepatic encephalopathy
M Romero‐Gómez, J Córdoba, R Jover, JA Del Olmo, M Ramírez, R Rey, ...
Hepatology 45 (4), 879-885, 2007
4132007
Phenotypic characterization of idiosyncratic drug‐induced liver injury: the influence of age and sex
MI Lucena, RJ Andrade, N Kaplowitz, M García‐Cortes, MC Fernández, ...
Hepatology 49 (6), 2001-2009, 2009
4102009
Outcome of acute idiosyncratic drug‐induced liver injury: long‐term follow‐up in a hepatotoxicity registry
RJ Andrade, MI Lucena, N Kaplowitz, B García‐Muņoz, Y Borraz, ...
Hepatology 44 (6), 1581-1588, 2006
4042006
HIV coinfection shortens the survival of patients with hepatitis C virus‐related decompensated cirrhosis
JA Pineda, M Romero‐Gómez, F Díaz‐García, JA Girón‐González, ...
Hepatology 41 (4), 779-789, 2005
3762005
The system can't perform the operation now. Try again later.
Articles 1–20